HomeCompareRHCO vs PFE

RHCO vs PFE: Dividend Comparison 2026

RHCO yields 6666.67% · PFE yields 6.13%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 RHCO wins by $1028095347812062.00M in total portfolio value
10 years
RHCO
RHCO
● Live price
6666.67%
Share price
$0.03
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1028095347812062.00M
Annual income
$998,628,545,336,266,700,000.00
Full RHCO calculator →
PFE
Pfizer Inc.
● Live price
6.13%
Share price
$28.08
Annual div
$1.72
5Y div CAGR
13.2%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$49.6K
Annual income
$26,258.71
Full PFE calculator →

Portfolio growth — RHCO vs PFE

📍 RHCO pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodRHCOPFE
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, RHCO + PFE cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
RHCO pays
PFE pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

RHCO
Annual income on $10K today (after 15% tax)
$566,666.67/yr
After 10yr DRIP, annual income (after tax)
$848,834,263,535,826,600,000.00/yr
PFE
Annual income on $10K today (after 15% tax)
$520.66/yr
After 10yr DRIP, annual income (after tax)
$22,319.90/yr
At 15% tax rate, RHCO beats the other by $848,834,263,535,826,600,000.00/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of RHCO + PFE for your $10,000?

RHCO: 50%PFE: 50%
100% PFE50/50100% RHCO
Portfolio after 10yr
$514047673906031.00M
Annual income
$499,314,272,668,133,360,000.00/yr
Blended yield
97.13%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on PFE right now

RHCO
No analyst data
Altman Z
3.2
Piotroski
7/9
PFE
Analyst Ratings
16
Buy
22
Hold
1
Sell
Consensus: Hold
Price Target
$27.50
-2.1% upside vs current
Range: $24.00 — $35.00
Altman Z
2.0
Piotroski
5/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

RHCO buys
0
PFE buys
8
PoliticianChamberTickerTypeAmountDate
Gilbert Cisneros🏢 House$PFE▲ Buy$1,001 - $15,0002026-02-10
Susan M. Collins🏛 Senate$PFE▲ Buy$15,001 - $50,0002026-02-03
James French Hill🏢 House$PFE▼ Sell$100,001 - $250,0002025-12-31
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-12-19
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-15
Ro Khanna🏢 House$PFE▼ Sell$1,001 - $15,0002025-09-05
Gilbert Cisneros🏢 House$PFE▼ Sell$1,001 - $15,0002025-08-05
Lisa McClain🏢 House$PFE▲ Buy$1,001 - $15,0002025-07-16
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
Ron Wyden🏛 Senate$PFE▼ Sell$1,001 - $15,0002025-06-03
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricRHCOPFE
Forward yield6666.67%6.13%
Annual dividend / share$2.00$1.72
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%13.2%
Portfolio after 10y$1028095347812062.00M$49.6K
Annual income after 10y$998,628,545,336,266,700,000.00$26,258.71
Total dividends collected$1026118102492338.88M$58.3K
Payment frequencyquarterlyquarterly
SectorStockHealthcare

Year-by-year: RHCO vs PFE ($10,000, DRIP)

YearRHCO PortfolioRHCO Income/yrPFE PortfolioPFE Income/yrGap
1← crossover$677,367$666,666.67$9,153$693.39+$668.2KRHCO
2$42,928,313$42,203,530.63$8,593$849.25+$42.92MRHCO
3$2,545,616,701$2,499,683,405.64$8,336$1,066.78+$2545.61MRHCO
4$141,255,910,403$138,532,100,533.89$8,437$1,384.80+$141255.90MRHCO
5$7,335,374,338,812$7,184,230,514,680.15$9,013$1,875.40+$7335374.33MRHCO
6$356,516,885,536,661$348,668,034,994,132.70$10,306$2,680.72+$356516885.53MRHCO
7$16,218,956,689,966,618$15,837,483,622,442,392.00$12,820$4,101.38+$16218956689.95MRHCO
8$690,711,023,145,868,900$673,356,739,487,604,600.00$17,673$6,826.70+$690711023145.85MRHCO
9$27,539,067,734,387,980,000$26,800,006,939,621,900,000.00$27,543$12,591.86+$27539067734387.95MRHCO
10$1,028,095,347,812,062,000,000$998,628,545,336,266,700,000.00$49,560$26,258.71+$1028095347812062.00MRHCO

RHCO vs PFE: Complete Analysis 2026

RHCOStock

Readen Holding Corp., through its subsidiaries, operates in the telecommunications, on line music and video, and recycling industries in the Netherlands and internationally. It engages in the purchase and production-planning, and the communication with hardware and application developers; purchases and distributes plastic products used in the recycling industry; owns a hotel and estates; sells and markets labels, prepaid vouchers, and simcards, as well as engages in physical and electronic distribution via terminals to retailers and distributors; and delivers glassfiber, Internet, VoIP, mobile, TVIP, PoIP, AoIP, and online services in the cloud and e-view managed energy. The company also offers glassfiber networks on an open bases for active operators and service providers; provides online music records that are distributed as MP3 files; engages in ship management and supply; trades in non-dairy products; produces and distributes a range of infant milk formulas; and supplies stable isotopes, deuterated solvents, and high purity materials for medical and chemical research. Readen Holding Corp is headquartered in Kortenhoef, the Netherlands.

Full RHCO Calculator →

PFEHealthcare

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic and women's health under the Premarin family and Eliquis brands; biologics, small molecules, immunotherapies, and biosimilars under the Ibrance, Xtandi, Sutent, Inlyta, Retacrit, Lorbrena, and Braftovi brands; and sterile injectable and anti-infective medicines, and oral COVID-19 treatment under the Sulperazon, Medrol, Zavicefta, Zithromax, Vfend, Panzyga, and Paxlovid brands. The company also provides medicines and vaccines in various therapeutic areas, such as pneumococcal disease, meningococcal disease, tick-borne encephalitis, and COVID-19 under the Comirnaty/BNT162b2, Nimenrix, FSME/IMMUN-TicoVac, Trumenba, and the Prevnar family brands; biosimilars for chronic immune and inflammatory diseases under the Xeljanz, Enbrel, Inflectra, Eucrisa/Staquis, and Cibinqo brands; and amyloidosis, hemophilia, and endocrine diseases under the Vyndaqel/Vyndamax, BeneFIX, and Genotropin brands. In addition, the company is involved in the contract manufacturing business. It serves wholesalers, retailers, hospitals, clinics, government agencies, pharmacies, and individual provider offices, as well as disease control and prevention centers. The company has collaboration agreements with Bristol-Myers Squibb Company; Astellas Pharma US, Inc.; Myovant Sciences Ltd.; Akcea Therapeutics, Inc; Merck KGaA; Valneva SE; BioNTech SE; and Arvinas, Inc. Pfizer Inc. was founded in 1849 and is headquartered in New York, New York.

Full PFE Calculator →
📬

Get this RHCO vs PFE comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

RHCO vs SCHDRHCO vs JEPIRHCO vs ORHCO vs KORHCO vs MAINRHCO vs JNJRHCO vs MRKRHCO vs ABBV

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.